Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at two dose levels: 2060 ug and 3090 ug against Aflibercept.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: EyePoint Pharmaceuticals, Inc.
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Documented diagnosis of wAMD in the study eye, with disease onset within 9 months prior to the Screening Visit.

• Previously treated with at least two anti VEGF intravitreal injections (i.e., bevacizumab, ranibizumab, or aflibercept) for wAMD per standard of care in the study eye within 6 months prior to the Screening Visit.

• BCVA ETDRS letter score of 35 letters (20/200 Snellen equivalent) to 80 letters (20/25 Snellen equivalent) in the study eye at the Screening Visit and on Day 1.

Exclusion Criteria:

• Central subfield thickness (CST) > 400 µm in the study eye at the Screening Visit or Day 1.

• Any concurrent intraocular condition in the study eye (e.g., cataract or glaucoma).

• Historical or active intraocular inflammation (grade trace or above) in the study eye, other than expected findings from routine cataract surgery.